# Alkermes Inc (NASDAQ: ALKS), Wilmington, OH – FDA Inspections

Source: https://www.keypedia.com/companies/alkermes-inc/c20f3273-400d-4b2e-a485-214b986ed7c2

> Inspection records and compliance data for Alkermes Inc in Wilmington, Ohio. 12 FDA inspections on record, 1 Form 483, last inspected October 19, 2023. Publicly traded as NASDAQ: ALKS.

---

## Details

- Name: Alkermes Inc
- FEI Number: 1000142940
- Address Line 1: 265 Olinger Cir
- City: Wilmington
- State: Ohio
- Zip Code: 45177
- Country Name: United States
- Address: 265 Olinger Cir, Wilmington, Ohio 45177, United States
- Country: United States

## Stock

- Stock ticker: ALKS
- Exchange: NASDAQ
- Share price: $46.98
- Market cap: $7.9B
- Price as of: November 13, 2026

## Related Documents

- [483 - Alkermes Inc - 2023-10-19](https://www.keypedia.com/records/483/alkermes-inc/95258bb8-236c-40b0-8ccb-1570c9ec1064) — source: FDA, date: October 19, 2023
- [FDA Inspection 1221397 - Alkermes Inc - 2023-10-19](https://www.keypedia.com/records/fda_inspections/alkermes-inc/e62e1695-5816-4ce8-a6a6-08f4055971c7) — classification: Voluntary Action Indicated (VAI), source: FDA, date: October 19, 2023
- FDA Inspection 1064719 - Alkermes Inc - 2018-07-27 — source: FDA, date: July 27, 2018
- FDA Inspection 1054407 - Alkermes Inc - 2018-05-04 — source: FDA, date: May 4, 2018
- FDA Inspection 1023169 - Alkermes Inc - 2017-08-14 — classification: No Action Indicated (NAI), source: FDA, date: August 14, 2017
- FDA Inspection 934564 - Alkermes Inc - 2015-04-17 — classification: No Action Indicated (NAI), source: FDA, date: April 17, 2015
- [FDA Inspection 934564 - Alkermes Inc - 2015-04-17](https://www.keypedia.com/records/fda_inspections/alkermes-inc/d4714a1c-4757-4945-890a-35a7ef06b349) — classification: No Action Indicated (NAI), source: FDA, date: April 17, 2015
- FDA Inspection 892884 - Alkermes Inc - 2014-08-15 — classification: No Action Indicated (NAI), source: FDA, date: August 15, 2014
- FDA Inspection 876673 - Alkermes Inc - 2014-04-23 — classification: No Action Indicated (NAI), source: FDA, date: April 23, 2014
- FDA Inspection 850614 - Alkermes Inc - 2013-09-23 — classification: No Action Indicated (NAI), source: FDA, date: September 23, 2013
- [FDA Inspection 837515 - Alkermes Inc - 2013-06-28](https://www.keypedia.com/records/fda_inspections/alkermes-inc/5496d93c-906f-491c-a9f9-c7e0a52cfaf9) — classification: Voluntary Action Indicated (VAI), source: FDA, date: June 28, 2013

## Related Companies

- [Shire Human Genetic Therapies, Inc.](https://www.keypedia.com/companies/shire-human-genetic-therapies-inc/7051823d-8cc7-4d72-8a82-a0de9bbb9497)
- [Murty Pharmaceuticals, Inc](https://www.keypedia.com/companies/murty-pharmaceuticals-inc/8d7f8024-f6fd-463e-b94f-63cd3b745e96)
- [Vertex Pharmaceuticals Incorporated](https://www.keypedia.com/companies/vertex-pharmaceuticals-incorporated/f2bc62b8-1ece-42d2-b058-39466a256c74)
- [AustarPharma, LLC](https://www.keypedia.com/companies/austarpharma-llc/05a402ea-dcb1-4900-9553-0a3a1b908183)
- [Agnitio Inc](https://www.keypedia.com/companies/agnitio-inc/6bcd09b9-e002-45bf-805c-0e4474b1bdfb)
- [Tedor Pharma, Inc.](https://www.keypedia.com/companies/tedor-pharma-inc/a9fa17c4-23c1-4bcf-ad03-bb9635bb063d)
- [Zydus Lifesciences Limited](https://www.keypedia.com/companies/zydus-lifesciences-limited/0de1df3a-c70c-43b9-9a35-4aac9b0413f4)
- [MSD International GmbH (Singapore Branch)](https://www.keypedia.com/companies/msd-international-gmbh-singapore-branch/acbc6490-ca0c-4304-8210-a35e4c4cbd79)
- [MW Encap Ltd.(NextPharma Edinburgh)](https://www.keypedia.com/companies/mw-encap-ltdnextpharma-edinburgh/e8cf1af5-d17a-4c79-ba7d-498a371fbc50)
- [Towa Pharmaceutical Europe, S.L.](https://www.keypedia.com/companies/towa-pharmaceutical-europe-sl/731d0b47-ce02-4781-8582-7090b456c5fe)

## Related Officers

- [Ucheabuchi C. Chudi-Nwankwor](https://www.keypedia.com/people/ucheabuchi-c-chudi-nwankwor/18b01d08-3cfd-4ace-97b2-5f54b6427661)
